Key Findings
- Across 26 double-blind RCTs (2,160 participants), omega-3 supplements with ≥60% EPA were associated with reduced depressive symptoms (standardized mean differences around −0.50 to −1.03 depending on formulation).
- DHA-predominant formulations did not show the same benefit — the effect was tied specifically to higher-EPA preparations.
- Omega-3 was often studied as an add-on to standard antidepressant care rather than as a replacement.
- Heterogeneity was high (differences in baseline depression, dose, and omega-3 status), so results should be interpreted with caution.